Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID)

Poitiers University Hospital

Status: Completed

Conditions: COVID-19; Chilblains

Treatments: Diagnostic Test: Biological Sample Collection

Study type: Interventional

Funder types: Other

Identifiers

NCT04387955

ACROVID

Details and patient eligibility

About

Cases of chilblains have been reported with an unusual frequency in France in the context of the COronaVirus Infectious Disease 2019 (COVID-19) epidemic. Some of these cases have been linked to a virological status in favour of a recent Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. Chilblains are acral inflammatory lesion typically reactive to cold (primary form). There are secondary forms acquired during autoimmune connectivitis such as lupus chilblain or hereditary forms related to type I Interferonopathy. An interferon type I signature has been described in these secondary forms of frostbite but also during the cytokine storm of severe forms of CoV-2 SARS infection. If cases of frostbite are indeed secondary to an SARS-CoV-2 infection, comparative analysis of their immunopathological profiles could provide a better understanding of the inflammatory mechanisms during COVID-19.

Enrollment: 11 patients

Sex: All

Ages: 12+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patient over the age of majority or a minor over 12 years of age accompanied by his/her legal representative
• Benefiting from a Social Security scheme
• Informed consent signed by the patient (if major) or by his legal representative (if minor) after clear, fair and appropriate information about the study.
• Red and swollen lesions of the hands and/or feet evolving for more than 24 hours in the context of a COVID-19 epidemic.
• PCR SARS-CoV-2 PCR on nasopharyngeal swab with results available, prior to the inclusion visit.
• Absence of fever or respiratory signs suggestive of COVID-19 for at least 14 days

Exclusion criteria

• A person who does not benefit from a Social Security scheme or who does not benefit from it through a third party.
• Patient who is subject to a judicial safeguard measure
• Allergy to local anaesthetic products
• Fever or respiratory signs suggestive of COVID-19 within 14 days

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

11 participants in 1 patient group

Acrovid

Other group

Description:

Cohort

Treatment:

Diagnostic Test: Biological Sample Collection